NDAINJECTIONINJECTABLE
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INNOHEP (tinzaparin sodium) is a low-molecular-weight heparin (LMWH) administered by subcutaneous injection. It is used for anticoagulation in venous thromboembolism (VTE) prevention and treatment. Tinzaparin works by potentiating the inhibition of factor Xa and thrombin, reducing clot formation.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30 intensity score), signaling transitional team focus toward value defense and potential rightsizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
Started Aug 2010
900 enrolled
Venous Thromboembolism
Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis
Started Dec 2005
541 enrolled
Deep Vein Thrombosis
Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
Started Feb 2004
40 enrolled
Primary Brain Tumor
Career Relevance
INNOHEP offers limited growth opportunities given its LOE-approaching lifecycle and zero linked job openings. Pharma professionals joining this team should expect focus on profit protection, formulary defense, and market maintenance rather than expansion initiatives. Career progression may be constrained unless product experiences unexpected lifecycle extension or acquisition-driven restructuring.
Worked on INNOHEP at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.